LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Fermé

SecteurSoins de santé

140.29 0.24

Résumé

Variation du prix de l'action

24h

Actuel

Min

140.04

Max

141.94

Chiffres clés

By Trading Economics

Revenu

394M

635M

Ventes

215M

2.6B

P/E

Moyenne du Secteur

12.653

35.733

BPA

3.02

Marge bénéficiaire

23.995

Employés

7,605

EBITDA

457M

1B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+20.72% upside

Dividendes

By Dow Jones

Prochains Résultats

29 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

442M

19B

Ouverture précédente

140.05

Clôture précédente

140.29

Sentiment de l'Actualité

By Acuity

31%

69%

92 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Biogen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 sept. 2025, 09:30 UTC

Acquisitions, Fusions, Rachats

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 sept. 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 20:37 UTC

Acquisitions, Fusions, Rachats

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 sept. 2025, 20:37 UTC

Acquisitions, Fusions, Rachats

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 sept. 2025, 20:36 UTC

Acquisitions, Fusions, Rachats

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 sept. 2025, 20:36 UTC

Acquisitions, Fusions, Rachats

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 sept. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 sept. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 sept. 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 sept. 2025, 20:20 UTC

Résultats

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept. 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 sept. 2025, 19:22 UTC

Résultats

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 sept. 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 sept. 2025, 18:59 UTC

Résultats

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept. 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 sept. 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 sept. 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 sept. 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 sept. 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 sept. 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 sept. 2025, 16:39 UTC

Acquisitions, Fusions, Rachats

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 sept. 2025, 16:39 UTC

Acquisitions, Fusions, Rachats

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 sept. 2025, 16:39 UTC

Acquisitions, Fusions, Rachats

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 sept. 2025, 16:39 UTC

Acquisitions, Fusions, Rachats

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 sept. 2025, 16:37 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

5 sept. 2025, 16:37 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Energy Roundup: Market Talk

5 sept. 2025, 16:37 UTC

Market Talk
Acquisitions, Fusions, Rachats

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 sept. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 16:16 UTC

Résultats

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Comparaison

Variation de prix

Biogen Inc prévision

Objectif de Prix

By TipRanks

20.72% hausse

Prévisions sur 12 Mois

Moyen 169.81 USD  20.72%

Haut 260 USD

Bas 118 USD

Basé sur 26 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

26 ratings

12

Achat

14

Maintien

0

Vente

Score Technique

By Trading Central

118.15 / 121.17Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

92 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat